SCHEMBL25877847

SCHEMBL25877847

CCN(C(=O)OC(C)(C)C)c1ccc(F)c([N+](=O)[O-])c1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.39
HIF1A Q16665 1/20 0.39
VCAM1 P19320 1/20 0.38
LMNA P02545 5/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
RECQL P46063 1/20 0.37
ITGB1 P05556 1/20 0.37
ITGA5 P08648 1/20 0.37
GAA P10253 3/20 0.36
PKM P14618 1/20 0.36
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
HTT P42858 2/20 0.36
MAPT P10636 2/20 0.36
THRB P10828 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
NPSR1 Q6W5P4 1/20 0.34
HCAR3 P49019 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL77393 0.85 ADRB2 (0.43) ALDH1A1LMNASMN1; SMN2RECQLGAA
SCHEMBL22897646 0.85 ALDH1A1 (0.39) ALDH1A1SMN1; SMN2GAAMEN1KMT2A
SCHEMBL18147782 0.85 ALDH1A1 (0.43) ALDH1A1HIF1AVCAM1LMNASMN1; SMN2
SCHEMBL13077189 0.84 ALDH1A1 (0.42) ALDH1A1HIF1AVCAM1LMNASMN1; SMN2
SCHEMBL22897818 0.82 ALDH1A1 (0.35) ALDH1A1LMNASMN1; SMN2MEN1KMT2A
SCHEMBL4969034 0.82 ALDH1A1 (0.45) ALDH1A1HIF1AVCAM1LMNASMN1; SMN2
SCHEMBL19205975 0.81 ALDH1A1 (0.40) ALDH1A1HIF1AVCAM1LMNASMN1; SMN2
SCHEMBL20045654 0.81 ALDH1A1 (0.34) ALDH1A1HIF1ALMNASMN1; SMN2GAA
SCHEMBL6081269 0.79 ALDH1A1 (0.57) ALDH1A1LMNASMN1; SMN2GAAMEN1
SCHEMBL25877846 0.77 MAPT (0.38) ALDH1A1LMNASMN1; SMN2GAAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230234943-A1 TREX1 INHIBITORS AND USES THEREOF TEMPEST THERAPEUTICS, INC. 2023-07-27 US disclosed
US-20230234943-A1 TREX1 INHIBITORS AND USES THEREOF TEMPEST THERAPEUTICS, INC. 2023-07-27 US disclosed
WO-2021263079-A1 TREX1 INHIBITORS AND USES THEREOF TEMPEST THERAPEUTICS, INC. (US) 2021-12-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234943-A1 TREX1 INHIBITORS AND USES THEREOF FEN1, ERCC4, DCLRE1B ALDH1A1 1451/4885HIF1A 824/4885VCAM1 3452/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.